No Prescription

No Prescription
HomeAlpha IndexCategories

Allergy

Anti Bacterial

Anti Convulsants

Anti Depressants

Anti Fungal

Anti Narcoleptic

Anti Viral

Antibiotics

Arthritis

Asthma

Birth Control

Blood Pressure

Cancer

Cardiovascular

Cholesterol

Diabetes

Diuretics

Eye Drops

Gastrointestinal

Hair Care

Herbal & Diet Supplements

Men's Health

Migraines

Muscle Relaxers

Nausea & Vomiting

Other

Pain Medicine

Pet Herbal Remedies

Prescription Drugs 1

Prescription Drugs 2

Prescription Drugs 3

Prescription Drugs 4

Prescription Drugs 5

Prescription Drugs 6

Prescription Drugs 7

Prescription Drugs 8

Prescription Drugs 9

Prescription Drugs 10

Prescription Drugs 11

Prescription Drugs 12

Prescription Drugs 13

Prescription Drugs 14

Prescription Drugs 15

Prescription Drugs 16

Prescription Drugs 17

Respiratory

Skin Care

Stop Smoking

Thyroid

Weight Loss

Women's Health

No Prescription

Alphabetical Index

Categories

EZETROL Zetia

No Prescription » Prescription Drugs 7 » EZETROL Zetia

Product Origin: EU (Turkey)

This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.

Medical Information:

Ezetimibe (e-ZET-e-mibe) is used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. Using this medicine may help prevent medical problems caused by such substances clogging the blood vessels.

Ezetimibe is a new kind of cholesterol-lowering drug. The older cholesterol-lowering drugs called "statins" reduce cholesterol by interfering with its production in the body. Zetia acts by diminishing the absorption of dietary cholesterol through the intestines.

Ezetimibe may be taken alone or with a statin drug. Because the two drugs fight cholesterol in different ways the Ezetimibe/statin combination has a greater impact than either drug alone.

Cholesterol--especially "bad" LDL cholesterol--promotes clogged arteries increasing the risk of heart attack and stroke. "Good" HDL cholesterol helps to prevent clogged arteries. Zetia lowers the bad cholesterol and raises the good. It also lowers total cholesterol readings and reduces levels of triglycerides (fats in the blood).

Cholesterol-lowering drugs are typically prescribed for people who either have heart disease or are in danger of developing it. For people at high risk of heart disease current guidelines call for considering drug therapy when LDL levels reach 130. For people at lower risk the cut-off is 160. For those at little or no risk it's 190.Inhibits absorption of cholesterol by the small intestine.Ezetimibe reduces the amount of cholesterol absorbed by the body.

Ezetimibe is used to treat high cholesterol. Ezetimibe is sometimes given with other cholesterol-lowering medications.

Buy EZETROL Zetia and other Prescription Drugs 7 products online at Medstore.

3667
Buy Online at Medstore - Click Here!

About EZETROL Zetia:

Product Type: Prescription Drugs 7

EZETROL ( Zetia Generic Ezetimibe )

EZETROL (Zetia Generic Ezetimibe)

Zetia Generic Ezetimibe

10mg 28 Tablets Zetia Generic Ezetimibe EZETROL

View more Prescription Drugs 7

Previous Product  Next Product

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.